Cognitive decline and cerebrospinal fluid biomarkers: a close relationship

Evaluation of: Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J. Alzheimers Dis. 34(4), 949–956 (2013). This study investigates cerebrospinal fluid biomarkers 42-amino acid form of amyloid-β (Aβ42) and total tau (T-tau) as predictors of cognitive decline in 326 subjects followed for 2 years and ranging from cognitively healthy elders to demented patients. In healthy controls, no relationship was found between cerebrospinal fluid biomarkers and cognitive decline. In subjective cognitive impairment individuals and mild cognitive impairment patients, T-tau had an impact on executive functions. The impact of T-tau was even larger on semantic memory in demented patients. The influence of Aβ42 level was small on speed and executive functions in mild cognitive impairment patients and moderate on semantic and verbal working memory in dementia patients. These findings demonstrate that cerebrospinal fluid biomarkers are good predic...

[1]  A Drzezga,et al.  Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration , 2002, Neurology.

[2]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[3]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[4]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[5]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[6]  N. Leclerc,et al.  The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons , 2010, Neuroscience.

[7]  Henrik Zetterberg,et al.  Cerebrospinal fluid biomarkers mirror rate of cognitive decline. , 2013, Journal of Alzheimer's disease : JAD.

[8]  A. Wallin,et al.  The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  K. Blennow,et al.  Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia , 1996, Journal of geriatric psychiatry and neurology.

[10]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[11]  K. Blennow,et al.  Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.

[12]  B. Reisberg,et al.  Global Deterioration Scale (GDS). , 1988, Psychopharmacology bulletin.

[13]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[14]  D. Royall,et al.  Bedside Assessment of Executive Cognitive Impairment: The Executive Interview , 1992, Journal of the American Geriatrics Society.

[15]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[16]  Marian Faux.  The executive interview , 1985 .

[17]  K. Blennow.  CSF biomarkers for mild cognitive impairment , 2004, Journal of internal medicine.

[18]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[19]  P. Deyn,et al.  Neuropsychological and behavioural correlates of CSF biomarkers in dementia , 2006, Neurochemistry International.